FolioLanternBeta
PBLSParabilis Medicines, Inc. · Insider ownership research

Parabilis Medicines, Inc. insiders: what they own and what they did with it

None of it through sales. No officer or director reported an open-market sale in this period.

Updated Oct 13, 2026 from SEC filings · covers Oct 14, 2025 to Oct 13, 2026
1
buyer among officers and directors (4 trades), past 12 months
0 of 14
officers and directors sold shares, past 12 months
Latest filing: Filed Jun 16 for a purchase from Jun 12 to Jun 15. Alan Sebulsky bought 18K shares ($474K). Filing
SEC ownership filings: 34 filed in the 12 months to Oct 13, 2026; 34 on record since Jun 9, 2026 · See the evidence

What stands out

Alan Sebulsky bought 30K shares for $724K, first on Jun 11, 2026. These are the first purchases by current officers or directors in the filings on record.Purchase, Jun 11, 2026

No officer or director sold shares in this period. 14 are left out

i
Left out: Barbara Weber, Thomas Kotarakos, Alexis Borisy, Jake Simson, Mohammed Benzaghou, Edward Fitzgerald, Helen Ho, Richard Klausner, Teresa Jurgensen, Krishna Yeshwant, Rohin Mhatre, Alan Sebulsky, Mathai Mammen and Craig Tendler (share of stake is being verified).
Disclosed company stock is not an insider's whole wealth.

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Jun 15, 2026Alan Sebulsky bought 9.1K shares ($240K).
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Alan Sebulsky
Director
9,065$26.49n/an/aJun 15, 2026Jun 16, 2026

Outside holders, reported separately

James Flynn, RA CAPITAL MANAGEMENT, L.P. and Guy Levy reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Parabilis Medicines, Inc. CEO selling stock?

No. Mathai Mammen reported no open-market sales in the past 12 months.

Are any Parabilis Medicines, Inc. insiders buying?

Yes. 1 officer or director reported 4 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold0 officers and directors: amount, % of holdings, trading plan
Who soldAmount% of holdingsTrading plan

Outside holder, reported separately: James Flynn (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: RA CAPITAL MANAGEMENT, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Guy Levy (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 14 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

InsiderHeld Oct 13, 2025SoldHeld Oct 13, 2026Still held
Barbara Weber
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Barbara Weber are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Barbara Weber

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Barbara Weber are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
2,599$1.85Dec 14, 2027$73K
13,646$4.62Sep 24, 2028$343K
16,245$4.82May 12, 2031$405K
32,490$3.14Feb 23, 2036$865K
20,215$20.00Jun 8, 2036$198K

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Thomas Kotarakos
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Thomas Kotarakos are complete.
Chief Financial Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Thomas Kotarakos

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Thomas Kotarakos are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
48,736$4.82Dec 18, 2031$1.2M
165,702$1.48Mar 27, 2034$4.7M
292,416$3.14Feb 17, 2036$7.8M

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Alexis Borisy
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Alexis Borisy are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Alexis Borisy

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alexis Borisy are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
20,215$20.00Jun 8, 2036$198K

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Jake Simson
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jake Simson are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Jake Simson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jake Simson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
20,215$20.00Jun 8, 2036$198K

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Mohammed Benzaghou
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Mohammed Benzaghou are complete.
Chief Medical Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Mohammed Benzaghou

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mohammed Benzaghou are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
357,398$2.42Sep 10, 2035$9.8M
243,680$3.14Feb 17, 2036$6.5M

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Edward Fitzgerald
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Edward Fitzgerald are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Edward Fitzgerald

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Edward Fitzgerald are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
16,245$1.85Jul 30, 2027$454K
16,245$4.82May 12, 2031$405K
32,490$3.14Feb 23, 2036$865K
20,215$20.00Jun 8, 2036$198K

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Helen Ho
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Helen Ho are complete.
Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Helen Ho

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Helen Ho are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
519,851$4.09Apr 20, 2036$13.3M

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Richard Klausner
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Richard Klausner are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Richard Klausner

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Richard Klausner are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
21,273$4.62Jun 27, 2028$535K
48,736$1.88Dec 10, 2034$1.4M
20,215$20.00Jun 8, 2036$198K

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Teresa Jurgensen
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Teresa Jurgensen are complete.
General Counsel
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Teresa Jurgensen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Teresa Jurgensen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
214,438$1.88Sep 4, 2034$6.0M
162,453$3.14Feb 17, 2036$4.3M

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Krishna Yeshwant
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Krishna Yeshwant are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Krishna Yeshwant

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Krishna Yeshwant are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
20,215$20.00Jun 8, 2036$198K

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Rohin Mhatre
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Rohin Mhatre are complete.
Officer
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Rohin Mhatre

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Rohin Mhatre are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
38,988$1.48Mar 27, 2034$1.1M
181,948$1.48Mar 27, 2034$5.1M
243,680$3.14Feb 17, 2036$6.5M

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Alan Sebulsky
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Alan Sebulsky are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Alan Sebulsky

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Alan Sebulsky are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
39,792$20.00Jun 8, 2036$389K

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Mathai Mammen
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Mathai Mammen are complete.
President & CEO, Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Mathai Mammen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mathai Mammen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
2,377,201$3.43Apr 20, 2033$62.6M
592,463$1.48Mar 27, 2034$16.8M
590,940$1.48Mar 27, 2034$16.7M
2,274,351$3.14Feb 23, 2036$60.6M

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Craig Tendler
!
Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Craig Tendler are complete.
Director
n/a0n/an/a
Vesting, gifts, unvested awards and holding lines for Craig Tendler

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Craig Tendler are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
16,245$2.42Mar 19, 2035$444K
20,294$39.36Aug 21, 2036$0

Estimate: options held × ($29.77 − strike price), using the most recent insider trade price on Form 4 (Jul 22, 2026), not a market close.

Holdings and share of stake for Parabilis Medicines, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

Known gaps and uncertainty14 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Parabilis Medicines, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology34 filings on record, 34 filed in the 12-month period, and how we read them

All 34 Forms 3, 4 and 5 on record for Parabilis Medicines, Inc. (SEC CIK 1657677), filed from Jun 9, 2026 to Aug 25, 2026; 34 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.